Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

A healthcare worker caring for a newborn in a clinical setting for an article about newborn malaria treatment

World’s first malaria treatment approved for newborn babies

By / / Good News For Humankind

Newborn malaria treatment reached a historic milestone as regulators approved Coartem Baby, the first antimalarial drug designed specifically for infants weighing under 5 kilograms. Developed through a partnership between Novartis and the non-profit Medicines for Malaria Venture, the dissolvable, cherry-flavored medication fills a gap that persisted for decades, leaving the most fragile newborns without a safe, approved option. Approval has been fast-tracked across eight African countries where need is greatest, with Novartis committing to largely not-for-profit pricing. For the youngest infants born into high-transmission environments, this changes everything.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record

U.K. commits £21.7 billion to carbon capture and storage across two industrial clusters

By / / Good News For Humankind

Carbon capture and storage gets a major boost as the UK commits up to £21.7 billion over 25 years to build CCS infrastructure across two historic industrial regions. The investment targets HyNet in the North West and the East Coast Cluster near Teesside, expected to create 4,000 direct jobs and support up to 50,000 long-term. Initial projects will remove more than 8.5 million tonnes of CO₂ annually while helping hard-to-decarbonize industries like steel, cement, and chemicals stay competitive. The UK’s North Sea geology offers an estimated 200 years of storage capacity, giving this commitment rare real-world credibility.

A researcher examining a vial in a cancer immunotherapy laboratory for an article about personalized mRNA cancer vaccine

Personalized mRNA vaccine keeps pancreatic cancer at bay six years after treatment

By / / Good news links

Personalized mRNA cancer vaccine shows remarkable results in a small but significant trial for pancreatic cancer, one of medicine’s most stubborn killers. Six years after treatment, seven of eight patients who mounted an immune response remain alive — extraordinary for a disease with a five-year survival rate below 13%. The custom-built vaccine targets genetic mutations unique to each patient’s tumor, training the immune system to eliminate remaining cancer cells after surgery. New findings suggest the immune response may be self-sustaining, with helper T cells replenishing the killer T cells that attack cancer. A larger Phase 2 trial is now underway.

A surgical team performing a complex organ procedure for an article about bladder transplant surgery, for article on bladder transplant

California surgeons perform the world’s first successful bladder transplant

By / / Good News For Humankind

Bladder transplant surgery has been successfully performed on a human patient for the first time in medical history. Oscar Larrainzar, a 41-year-old California father of four, received a donor bladder and kidney simultaneously in early May 2025, after cancer treatment left him without either organ. He has since been taken off dialysis entirely. The procedure was developed over four years by surgeons at USC and UCLA, who now plan a formal clinical trial to refine the technique. For patients who have lost bladder function, transplantation is no longer theoretical.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

Annual jab for HIV protection passes trial hurdle

By / / Good News For Humankind

A once-yearly HIV prevention shot has just cleared its first safety trial, with the drug lenacapavir still detectable in participants’ bodies a full 56 weeks after a single injection. That’s a hopeful sign for people who find daily prevention pills hard to maintain — whether because of stigma, unstable housing, or simply the grind of remembering. Earlier trials of twice-yearly lenacapavir already showed striking results, and researchers are now testing whether one shot a year could work just as well. With nearly 40 million people living with HIV globally, a prevention tool this simple could reshape what protection looks like — especially for communities where daily medication has never been realistic.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record

France runs fusion reactor for record 22 minutes

By / / Good News For Humankind

A fusion reactor in southern France has kept a hydrogen plasma stable for 1,337 seconds — more than 22 minutes — beating the previous record by roughly 25%. The WEST Tokamak pulled this off using just 2 megawatts of heating power, and crucially, without damaging the reactor’s interior, which is the part that has tripped up so many earlier attempts. The data feeds directly into ITER, the much larger international fusion project being built nearby. Net energy gain — the real threshold for practical fusion — still hasn’t been reliably crossed, and this milestone doesn’t change that. But each stable second brings the dream of clean, limitless energy closer to something the world can actually build.

Two people holding hands, for article on Parkinson's infusion device, for article on Onapgo approval

U.S. approves “milestone” Parkinson’s treatment for 2025 release

By / / Good News For Humankind

Onapgo, a new wearable approved by the FDA, will give Americans with Parkinson’s a continuous, non-surgical way to manage their symptoms when it launches in late 2025. The small device delivers a steady infusion of apomorphine under the skin, bypassing the digestive system entirely — a real advantage for a disease that often slows digestion and makes pills unpredictable. In trials, patients cut their daily “off” episodes — those rough stretches when medication wears off and tremors return — by nearly two and a half hours on average. The therapy has quietly helped European patients for about three decades, and its U.S. arrival opens a gentler path for the roughly one million Americans living with Parkinson’s, part of a growing global push toward more humane, individualized care.

A doctor reviewing a prescription pad in a clinical setting for an article about non-opioid pain drug approval

FDA approves first non-opioid pain drug in more than 20 years

By / / Good News For Humankind

The FDA’s approval of Journavx (suzetrigine), a first-in-class non-opioid pain drug, marks the most significant shift in acute pain treatment in over two decades. Developed by Vertex Pharmaceuticals, the drug blocks a specific sodium channel in the peripheral nervous system, stopping pain signals before they reach the brain without engaging the opioid pathways linked to addiction and overdose. Two rigorous clinical trials confirmed its effectiveness for moderate to severe acute pain. With more than 500,000 opioid overdose deaths in the U.S. since 1999, this approval offers patients and doctors a genuinely new choice — one that treats real pain without the shadow of dependence.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record

China sets new fusion endurance record of over a thousand seconds

By / / Good News For Humankind

Fusion energy took a real step forward this month: a reactor in China held superheated plasma stable for 1,066 seconds — more than 17 minutes, and over double the 403-second record the same machine set in 2023. The Experimental Advanced Superconducting Tokamak in Hefei pulled it off after engineers doubled the system’s power output while keeping the reaction from collapsing, which is the hardest part of fusion research. Sustained stability like this is exactly what a future fusion plant would need to actually generate continuous electricity. Findings from EAST will also feed directly into ITER, the massive international reactor rising in southern France. It’s a reminder that the dream of clean, nearly limitless energy is being built one patient breakthrough at a time.

A medical researcher reviewing cancer treatment data in a laboratory, for an article about breast cancer immunotherapy

Australian researchers nearly double cure rates for the most common breast cancer

By / / Good News For Humankind

Breast cancer immunotherapy has achieved a breakthrough in Australia, with researchers nearly doubling cure rates for hormone receptor-positive breast cancer — the most common form of the disease, representing roughly 70% of all diagnoses worldwide. A combination of immunotherapy and chemotherapy produced pathological complete responses, meaning no detectable cancer remained at surgery, at rates far exceeding historical norms below 20%. Because HR+ tumors have long resisted immunotherapy, this result marks a significant turning point. With over 2.3 million breast cancer cases diagnosed globally each year, most of them HR+, the potential scale of impact is enormous.